Megakaryoblast

Megakaryoblasts are the earliest morphologically identifiable precursors of the megakaryocytic lineage in the bone marrow, originating from hematopoietic stem cells through the megakaryocyte-erythroid progenitor (StatPearls, 2023). These cells are characterized by a high nuclear-to-cytoplasmic ratio and the expression of lineage-specific surface markers such as CD41 and CD61 (PathologyOutlines, 2022). Their primary biological function is to undergo endomitosis—a process of DNA replication without cytoplasmic division—to eventually mature into large, polyploid megakaryocytes that shed platelets into the circulation (NIH, 2021). In clinical pathology, the uncontrolled proliferation of these cells is the hallmark of Acute Megakaryoblastic Leukemia (AMKL), a condition frequently associated with Down syndrome or specific chromosomal translocations (NCI, 2023). While the megakaryoblast itself is a cell type rather than a single molecular target, it expresses the thrombopoietin receptor (MPL), which is the primary site of action for several therapeutic agents (PubChem, 2024). Drugs such as romiplostim and eltrombopag act as agonists at this receptor to stimulate the maturation of these precursors and increase platelet counts in patients with thrombocytopenia (FDA, 2023). Understanding the regulation and maturation of megakaryoblasts is critical for the treatment of both hematologic malignancies and disorders of primary hemostasis.

Other names

Platelet precursor cellMegakaryocyte progenitorCFU-MegStage I megakaryocyte

Agonism of the thrombopoietin receptor (MPL) expressed on the surface of these precursor cells to stimulate intracellular signaling pathways (JAK2/STAT) that drive proliferation and maturation into platelet-producing megakaryocytes.